PAOLI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.898
EU - Europa 1.204
AS - Asia 723
SA - Sud America 68
AF - Africa 11
OC - Oceania 7
Totale 3.911
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.884
RU - Federazione Russa 494
IT - Italia 289
SG - Singapore 204
CN - Cina 190
HK - Hong Kong 150
IE - Irlanda 91
SE - Svezia 78
KR - Corea 69
BR - Brasile 51
FI - Finlandia 45
DE - Germania 43
PL - Polonia 39
FR - Francia 35
JO - Giordania 32
VN - Vietnam 27
CH - Svizzera 26
GB - Regno Unito 22
IN - India 18
NL - Olanda 17
ID - Indonesia 13
ES - Italia 10
CA - Canada 8
AU - Australia 7
AR - Argentina 6
CI - Costa d'Avorio 4
MX - Messico 4
JP - Giappone 3
RO - Romania 3
TR - Turchia 3
UA - Ucraina 3
VE - Venezuela 3
BJ - Benin 2
CL - Cile 2
EC - Ecuador 2
IR - Iran 2
MM - Myanmar 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PY - Paraguay 1
SA - Arabia Saudita 1
SN - Senegal 1
UZ - Uzbekistan 1
Totale 3.911
Salva come PNG Salva come JPEG
Città #
Santa Clara 492
Ashburn 226
Fairfield 191
Singapore 140
Hong Kong 128
Woodbridge 94
Chandler 93
Dublin 91
Seattle 81
Houston 74
Cambridge 72
Seoul 69
Florence 61
Wilmington 61
Hefei 44
Warsaw 39
Beijing 38
Altamura 37
Lawrence 30
Princeton 28
Bern 26
Los Angeles 24
Ann Arbor 23
Dallas 22
Paris 22
Buffalo 20
Rome 20
Helsinki 17
Moscow 16
Munich 16
Shanghai 16
Clifton 15
Turku 15
London 14
Milan 14
Boston 13
Jakarta 12
Medford 12
Boardman 10
Bremen 10
Mumbai 10
New York 10
Ho Chi Minh City 8
Kent 8
Redondo Beach 8
Melbourne 7
Dearborn 6
Frosinone 6
San Diego 6
São Paulo 6
Atlanta 5
Lappeenranta 5
Latina 5
Toronto 5
Abidjan 4
Amsterdam 4
Barcelona 4
Cagliari 4
Dong Ket 4
Düsseldorf 4
Falls Church 4
Hanoi 4
Napoli 4
Norwalk 4
Siena 4
Andover 3
Chengdu 3
Faenza 3
Haiphong 3
Monza 3
Pomigliano d'Arco 3
Secaucus 3
The Dalles 3
Acquaviva delle Fonti 2
Amman 2
Ancona 2
Belo Horizonte 2
Bengaluru 2
Bergamo 2
Biên Hòa 2
Brescia 2
Brooklyn 2
Burghausen 2
Caponago 2
Casalecchio di Reno 2
Chennai 2
Cotonou 2
Elk Grove Village 2
Falkenstein 2
Fano 2
Foligno 2
Frankfurt am Main 2
Fuzhou 2
Gambettola 2
Genova 2
Hangzhou 2
Indianapolis 2
Johannesburg 2
Mexico City 2
Modena 2
Totale 2.643
Salva come PNG Salva come JPEG
Nome #
Sviluppo e gestione di studi clinici indipendenti di Fase I/II nelle Neoplasie Mieloproliferative Croniche 225
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 211
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 208
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 208
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 187
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 177
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 176
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 173
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 172
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 169
Kaposi Sarcoma in a patient treated with Ruxolitinib 168
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 164
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms 153
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 148
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 148
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 147
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group 142
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs 139
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 137
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 129
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 120
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 120
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 120
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 117
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 114
Totale 3.972
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021137 0 0 0 0 0 10 7 20 27 37 28 8
2021/2022154 5 11 15 4 3 7 5 20 11 6 22 45
2022/2023505 43 96 34 29 29 77 61 28 60 6 15 27
2023/2024233 12 20 24 21 17 24 5 68 6 13 12 11
2024/20251.472 49 115 79 237 374 244 38 108 44 57 66 61
2025/2026772 172 187 122 93 177 21 0 0 0 0 0 0
Totale 3.972